Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cisplatin Resistance in an Ovarian Carcinoma Is Associated With a Defect in Programmed Cell Death Control Through XIAP Regulation

1 Jan 2003

Abstract excerpt

Chemoresistance is a major impediment to the successful treatment of cancer. It involves various mechanisms, including defects in the apoptosis program that is induced by anticancer drugs. To further explore the mechanisms underlying the development of chemoresistance in ovarian carcinoma after cisplatin (CDDP) treatment, we compared the effect of CDDP on expression of X-linked inhibitor of apoptosis protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chemotherapy-induced organ toxicity mitigation
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12725530
DOI: 10.3727/096504003108748410

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cisplatin Resistance in an Ovarian Carcinoma Is Associated With a Defect in Programmed Cell Death Control Through XIAP RegulationPMID 12725530Read ↗

Apoptosis and Chemoresistance in Human Ovarian Cancer: Is Xiap a Determinant?Semantic proximity Read ↗

Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell linesSemantic proximity Read ↗

Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.Semantic proximity Read ↗

The p53 Upregulated Modulator of Apoptosis (PUMA) Chemosensitizes Intrinsically Resistant Ovarian Cancer Cells to Cisplatin by Lowering the Threshold Set by Bcl-xL and Mcl-1Semantic proximity Read ↗

Molecular mechanisms of cisplatin resistance in ovarian cancerSemantic proximity Read ↗

Chemoresistance in human ovarian cancer: the role of apoptotic regulatorsSemantic proximity Read ↗

Acquisition of chemoresistance in a human ovarian carcinoma cell line is linked to a defect in cell cycle controlSemantic proximity Read ↗

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.Semantic proximity Read ↗

Cisplatin resistance and oncogenes - a reviewSemantic proximity Read ↗

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell linesSemantic proximity Read ↗

Akt-Mediated Cisplatin Resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-Dependent Mitochondrial Death PathwaySemantic proximity Read ↗

The mTORC2 Component Rictor Contributes to Cisplatin Resistance in Human Ovarian Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.